NCT05044897View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

SI-B001

administration weekly by intravenous infusion（QW）.

Trial Locations (3)

200000

Shanghai Oriental Hospital, Shanghai

Unknown

The Second Affiliated Hospital of Guilin Medical University, Guilin

The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY